Key result
Initiation of more effective antihypertensive regimens is recommended over low-efficacy monotherapy, as apparent early response differences largely reflect physiological noise rather than true variation.
Answers are grounded in this paper and cite their sources.
The authors argue that apparent interindividual variability in early blood pressure response is largely physiological noise, advocating for more proactive and intensive antihypertensive regimens in older adults.
We thank Kow et al for their thoughtful commentary on our paper.1 Their letter raises three points: (1) response to treatment is impacted by baseline blood pressure (BP), (2) interindividual variability in BP response, and (3) safety considerations with more intensive upfront BP lowering. We agree that the absence of individual baseline BP data is a limitation, and we acknowledge it as such. However, the impact of baseline BP is unlikely to be substantial. Meta-analyses of trials indicate each 10 mm Hg higher pre-treatment systolic BP is only associated with an average additional 1-2 mmHg systolic BP reduction with monotherapy (BPmodel.org). Also, Kow et al suggest that BP lowering treatment is often commenced near diagnostic thresholds in older adults. In fact, starting systolic BP levels are generally >150 mmHg in adults who are commenced on treatment and in practice, treatment inertia is most pronounced in people whose BP is only marginally above target.2 We disagree with the implication that apparent differences in early BP response reflect true interindividual variation in treatment effect. Two individuals may appear to have very different initial responses to the same regimen, but empiric data show this is principally due to noise (eg, physiological BP variability) rather than signal (true inter-individual response differences). The true long-term treatment response is likely to be similar between individuals whose BP initially rises and those in whom it initially drops by >20 mmHg.3 In routine care, reliable tools to distinguish a “good responder” from a “poor responder” on the basis of short-term BP changes alone do not currently exist. An n-of-1 crossover trial by Sundström et al demonstrated that identifying meaningful differences in individual treatment response requires a structured year-long process with multiple repeat 24-hour ambulatory BP measures. They also showed personalized treatment choice would on average achieve only 4.4 mmHg greater systolic BP reduction–far less than the efficacy of adding another drug class.4 Rather than undertaking a challenging protocol, we think that initiation of more effective antihypertensive medication regimen would be appropriate. Kow et al raise the issue of safety, without noting that undertreatment of high BP carries important risks in terms of foregone opportunity to prevent fatal or disabling cardiovascular events. When the benefits and risks of intensive BP lowering in the elderly are quantified in terms of both frequency and severity, almost all individuals are expected to have net benefit.5 BP control rates remain very low in the US and internationally. If the collective aim is to reduce the burden of death and disability, a more proactive approach to achieving BP control is warranted. Prescribing guided by randomized trial evidence—determining upfront what treatment is most appropriate for an individual may be the most pragmatic and scalable path forward. We are testing this in an ongoing randomized controlled trial (NCT06935760). Continuing to rely on low efficacy monotherapy risks perpetuating decades of slow progress against the leading modifiable cause of death and disability worldwide. None declared. None declared. Dr Nelson Wang is supported by the Heart Foundation Post-doctoral Fellowship 108288-2024_PDF. Professor Rodgers is employed by The George Institute for Global Health (TGI) and Imperial College London and seconded part-time to George Medicines Pty Ltd (GM). TGI has submitted patent applications in respect of low fixed-dose combination products for the treatment of cardiovascular or cardiometabolic disease, and Professor Rodgers is listed as one of the inventors; (Granted: US 10,369,156; US 10,799,487; US 10,322,117; US 11,033,544; US 11,478,462; Pending: US 17/932,982; US 18/446,268; US 17/598,122; US 17/317,614). Professor Rodgers does not have a financial interest in these patent applications or investments. Professor Rodgers has served on a Data and Safety Monitoring Board for a trial sponsored by Idorsia. Professor Rodgers is supported by an Investigator Grant from the National Health and Medical Research Council of Australia (GNT 1160734).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a letter in Hypertension. Intensive upfront antihypertensive therapy vs. Low efficacy monotherapy was evaluated. Initiation of more effective antihypertensive regimens is recommended over low-efficacy monotherapy, as apparent early response differences largely reflect physiological noise rather than true variation.
Synapse has enriched 10 related papers. Consider them for comparative context: